Metastatic Lymph Node Distribution in the Ileum Mesentery of Cecal and Proximal Ascending Colon Cancer

A Prospective Multicenter Observational Study on Metastatic Lymph Node Distribution of Ileum Mesentery in Cecal Cancer and Proximal Ascending Colon Cancer

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07149623

Enrollment

406

Registered

2025-09-02

Start date

2025-09-01

Completion date

2030-09-01

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Brief summary

Based on the above considerations, our team maintains that it is currently imperative to conduct a prospective multicenter registry study. This study would involve sectioning and submitting fresh surgical specimens from the ileum mesentery of patients undergoing radical resection for cecal cancer and proximal ascending colon cancer (right-sided colon cancer). The objectives are to: Clarify the distribution range of metastatic lymph nodes within the ileum mesentery; Conduct survival follow-up on enrolled patients; Provide reliable evidence-based medical evidence for the individualized determination of ileal resection margins.

Interventions

PROCEDUREExperimental

sectioning and submitting fresh surgical specimens from the ileum mesentery

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Age 18-80 years; ECOG performance status 0-2; Histologically confirmed colon adenocarcinoma; Surgical specimen confirming tumor location at: ileocecal valve orifice (cecal cancer), OR proximal ascending colon cancer with tumor ≤5 cm from ileocecal valve; Clinical stage: cT2-4aN0M0, OR cTanyN+M0; Patient and family members fully understand the study and voluntarily participate by signing informed consent

Exclusion criteria

Synchronous or metachronous multiple primary colon cancers (Note: Synchronous: diagnosed within 6 months; Metachronous: diagnosed \>6 months apart); Preoperative neoadjuvant therapy (chemotherapy, immunotherapy, or radiotherapy) that may cause tumor regression or downstaging; Patients undergoing salvage radical surgery after endoscopic resection.

Design outcomes

Primary

Measure	Time frame
Metastatic rate in mesenteric lymph nodes	1 month after surgery

Secondary

Measure	Time frame
5-year overall survival	5 years after surgery
Distribution of metastatic lymph nodes in the mesentery	1 month after surgery
3-year disease-free survival	3 years after surgery

Contacts

Primary ContactZhen Sun

sunzhen39@pumch.cn86-18910598831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026